All In Biotech

Free tool

FAERS Monitor: Ztalmy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215904 or its brand name (Ztalmy, Ganaxolone). Reports on generic versions are filed under their own applications.

Reports

670

Serious

350

52% of reports

Hospitalization

112

Death reported

16

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure204
  • product dose omission issue101
  • drug ineffective88
  • somnolence58
  • change in seizure presentation43
  • pneumonia31
  • off label use28
  • vomiting24
  • fatigue15
  • illness15
  • weight decreased15
  • pyrexia12
  • urinary tract infection11
  • death10
  • weight increased10

Reports by year received

View as table
YearReports
20212
202224
2023109
2024197
2025279
202659

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,489 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
change in seizure presentationSignal432237.11657.487,648
seizureSignal20455.549.510,912
product dose omission issueSignal10110.89.0899
somnolenceSignal589.07.1411
illnessSignal154.62.839
pneumoniaSignal313.02.140
drug ineffectiveSignal882.11.753
urinary tract infectionSignal112.01.15
weight decreased151.71.04
vomiting241.61.15
weight increased101.40.81
pyrexia121.10.60
off label use281.00.70
fatigue150.60.44
death100.40.211

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.